← Leaderboards
Martin Lawrence Moore
Emory University
$6,408,187
Attributed
$7,598,086
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–19$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,598,086 · 8
By mechanism
U19$2,675,964 · 2
R01$1,908,619 · 1
R44$1,563,412 · 1
R43$816,386 · 2
R56$369,625 · 1
K22$264,080 · 1
Top collaborators
- Roderick Tang4 shared
- Young Man Kwon1 shared
- Fu Shi Quan1 shared
Most similar at Emory University
Same institution · by research overlap
- Larry J Anderson$1,008,400
- Sang-Moo Kang$13,182,056
Others in their field
Top investigators on “Hospitalization”
- Larry Arthur$288,323,000
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$230,275,254
- Judith S. Currier · University Of California Los Angeles$223,149,861
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$221,207,102
- Lawrence Corey · Fred Hutchinson Cancer Center$217,829,567
- Daniel R Kuritzkes · Brigham And Women'S Hospital$179,610,394
Research focus
HospitalizationRespiratory Syncytial VirusInfantRespiratory Syncytial Virus InfectionsVirus DiseasesVirusProteinsViralVirulenceInfectionIn VivoImmune ResponseLaboratoriesVaccinesLeadCessation Of LifeLungGeneticProductionCellsBronchiolitisChimeric ProteinsBaseImmunity
Grant awards (20)
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$339,597
R44 · FY2019 · AI
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$999,722
R44 · FY2018 · AI
Rationally designed live attenuated RSV vaccines$369,625
R56 · FY2018 · AI · contact PI
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$224,093
R44 · FY2017 · AI
Development of polyvalent inactivated rhinovirus vaccine$216,388
R43 · FY2017 · AI
Respiratory syncytial virus strain differences in bronchiolits and asthma$521,535
U19 · FY2015 · AI · contact PI
Respiratory syncytial virus strain differences in bronchiolits and asthma$2
U19 · FY2015 · AI · contact PI
Respiratory syncytial virus strain differences in bronchiolits and asthma$633,877
U19 · FY2014 · AI · contact PI
Role of the Respiratory Syncytial Virus Fusion Protein in Airway Mucus Induction$382,753
R01 · FY2014 · AI · contact PI
Respiratory syncytial virus strain differences in bronchiolits and asthma$503,724
U19 · FY2013 · AI · contact PI
Role of the Respiratory Syncytial Virus Fusion Protein in Airway Mucus Induction$359,811
R01 · FY2013 · AI · contact PI
Respiratory syncytial virus strain differences in bronchiolits and asthma$485,063
U19 · FY2012 · AI · contact PI
Role of the Respiratory Syncytial Virus Fusion Protein in Airway Mucus Induction$382,802
R01 · FY2012 · AI · contact PI
Respiratory syncytial virus strain differences in bronchiolits and asthma$531,763
U19 · FY2011 · AI · contact PI
Role of the Respiratory Syncytial Virus Fusion Protein in Airway Mucus Induction$386,682
R01 · FY2011 · AI · contact PI
Virus-like particle vaccines against respiratory syncytial virus$299,999
R43 · FY2011 · AI
Role of the Respiratory Syncytial Virus Fusion Protein in Airway Mucus Induction$396,571
R01 · FY2010 · AI · contact PI
Virus-like particle vaccines against respiratory syncytial virus$299,999
R43 · FY2010 · AI
Mechanisms of Respiratory Syncytial Virus-Induced Mucus" Viral Strain Dependence$107,200
K22 · FY2010 · AI · contact PI
Mechanisms of Respiratory Syncytial Virus-Induced Mucus" Viral Strain Dependence$156,880
K22 · FY2009 · AI · contact PI